COVID-19 VaccinE Response in Rheumatology Patients
Public ClinicalTrials.gov record NCT05080218. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The SARS-CoV-2 Vaccine Response and Safety in Rheumatology Patients and the Influence of Temporary Interruptions in Immunomodulatory Therapy
Study identification
- NCT ID
- NCT05080218
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Jeffrey Curtis
- Other
- Enrollment
- 841 participants
Conditions and interventions
Interventions
- Abatacept Drug
- Baricitinib Drug
- Canakinumab Injection Drug
- Ixekizumab Drug
- Secukinumab Drug
- TNF Inhibitor Drug
- Tofacitinib Drug
- Upadacitinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 14, 2021
- Primary completion
- Apr 3, 2024
- Completion
- May 27, 2024
- Last update posted
- May 1, 2025
2021 – 2024
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Illumination Health/Bendcare | Hoover | Alabama | 35244 | — |
| Rheumatology Care Center | Hoover | Alabama | 35244 | — |
| Arizona Arthritis & Rheumatology Research, PLLC | Phoenix | Arizona | 85032 | — |
| Attune Health | Beverly Hills | California | 90211 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| University of Pennsylvania Medical Center | Philadelphia | Pennsylvania | 19104 | — |
| Metroplex Clinical Research Center | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05080218, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 1, 2025 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05080218 live on ClinicalTrials.gov.